Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors

Cold Spring Harbor Symposia on Quantitative Biology

Volumn 70, Issue , 2005, Pages 251-261

  Zender, L ^a   Xue, W ^a   Cordon Cardo C ^b   Hannon, G J ^a   Lucito, R ^a   Powers, S ^a   Flemming, P ^c   Spector, M S ^a   Lowe, S W ^a,d  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SHORT HAIRPIN RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CANCER INVASION; CANCER MORTALITY; CANCER STEM CELL; CONFERENCE PAPER; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; GENE EXPRESSION; GENE TRANSFER; GENETIC ANALYSIS; GENETIC TRANSDUCTION; HISTOPATHOLOGY; LIVER CELL CARCINOMA; LIVER DEVELOPMENT; MICROARRAY ANALYSIS; MOUSE; MUTATION; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; TUMOR MODEL; TUMOR SUPPRESSOR GENE; ADULT; ARTICLE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LIVER TUMOR; RETRANSPLANTATION; TUMOR INVASION;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; GENE TARGETING; GENES, REPORTER; GENES, TUMOR SUPPRESSOR; GREEN FLUORESCENT PROTEINS; HEPATOCYTES; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MULTIPOTENT STEM CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENES; RECOMBINANT PROTEINS; RNA INTERFERENCE; TRANSDUCTION, GENETIC; TUMOR STEM CELLS;

MURINAE;

EID: 33746441453     PISSN: 00917451     EISSN: None     Source Type: Book Series    
DOI: 10.1101/sqb.2005.70.059     Document Type: Conference Paper

References (56)

1. Al Hajj M. and Clarke M.F. 2004. Self-renewal and solid tumor stem cells. Oncogene 23: 7274.
2. Alison M.R. and Lovell M.J. 2005. Liver cancer: The role of stem cells. Cell Prolif. 38: 407.
3. Baik I., Becker P.S., DeVito W.J., Lagiou P., Ballen K., Quesenberry P.J., and Hsieh C.C. 2004. Stem cells and prenatal origin of breast cancer. Cancer Causes Control 15: 517.
4. Block G.D., Locker J., Bowen W.C., Petersen B.E., Katyal S., Strom S.C., Riley T., Howard T.A., and Michalopoulos G.K. 1996. Population expansion, clonal growth, and specific differentiation patterns in primary cultures of hepatocytes induced by HGF/SF, EGF and TGF alpha in a chemically defined (HGM) medium. J. Cell Biol. 132: 1133.
5. Braun L., Goyette M., Yaswen P., Thompson N.L., and Fausto N. 1987. Growth in culture and tumorigenicity after transfection with the ras oncogene of liver epithelial cells from carcinogen-treated rats. Cancer Res. 47: 4116.
6. Bruix J., Boix L., Sala M., and Llovet J.M. 2004. Focus on hepatocellular carcinoma. Cancer Cell 5: 215.
7. Buendia M.A. 2000. Genetics of hepatocellular carcinoma. Semin. Cancer Biol. 10: 185.
8. Dabeva M.D. and Shafritz D.A. 2003. Hepatic stem cells and liver repopulation. Semin. Liver Dis. 23: 349.
9. Deane N.G., Parker M.A., Aramandla R., Diehl L., Lee W.J., Washington M.K., Nanney L.B., Shyr Y., and Beauchamp R.D. 2001. Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. Cancer Res. 61: 5389.
10. Dickins R.A., Hemann M.T., Zilfou J.T., Simpson D.R., Ibarra I., Hannon G.J., and Lowe S.W. 2005. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat. Genet. 37: 1289.
11. Dumble M.L., Croager E.J., Yeoh G.C., and Quail E.A. 2002. Generation and characterization of p53 null transformed hepatic progenitor cells: Oval cells give rise to hepatocellular carcinoma. Carcinogenesis 23: 435.
12. Guo D., Fu T., Nelson J.A., Superina R.A., and Soriano H.E. 2002. Liver repopulation after cell transplantation in mice treated with retrorsine and carbon tetrachloride. Transplantation 73: 1818.
13. Gupta S., Aragona E., Vemuru R.P., Bhargava K.K., Burk R.D., and Chowdhury J.R. 1991. Permanent engraftment and function of hepatocytes delivered to the liver: Implications for gene therapy and liver repopulation. Hepatology 14: 144.
14. Hannon G.J. and Rossi J.J. 2004. Unlocking the potential of the human genome with RNA interference. Nature 431: 371.
15. Harada N., Oshima H., Katoh M., Tamai Y., Oshima M., and Taketo M.M. 2004. Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations. Cancer Res. 64: 48.
16. Hemann M.T., Fridman J.S., Zilfou J.T., Hernando E., Paddison P.J., Cordon-Cardo C., Hannon G.J., and Lowe S.W. 2003. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat. Genet. 33: 396.
17. Hemann M.T., Bric A., Teruya-Feldstein J., Herbst A., Nilsson J.A., Cordon-Cardo C., Cleveland J.L., Tansey W.P., and Lowe S.W. 2005. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 436: 807.
18. Huo T.I., Wang X.W., Forgues M., Wu C.G., Spillare E.A., Giannini C., Brechot C., and Harris C.C. 2001. Hepatitis B virus X mutants derived from human hepatocellular carcinoma retain the ability to abrogate p53-induced apoptosis. Oncogene 20: 3620.
19. Jhappan C., Stahle C., Harkins R.N., Fausto N., Smith G.H., and Merlino G.T. 1990. TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 61: 1137.
20. Kim S.O., Park J.G., and Lee Y.I. 1996. Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: Implications of IGF-I receptor gene activation by hepatitis B virus X gene product. Cancer Res. 56: 3831.
21. Kusano N., Shiraishi K., Kubo K., Oga A., Okita K., and Sasaki K. 1999. Genetic aberrations detected by comparative genomic hybridization in hepatocellular carcinomas: Their relationship to clinicopathological features. Hepatology 29: 1858.
22. Laconi S., Curreli F., Diana S., Pasciu D., De Filippo G., Sarma D.S., Pani P., and Laconi E. 1999. Liver regeneration in response to partial hepatectomy in rats treated with retrorsine: A kinetic study. J. Hepatol. 31: 1069.
23. Lewis B.C., Klimstra D.S., Socci N.D., Xu S., Koutcher J.A., and Varmus H.E. 2005. The absence of p53 promotes metastasis in a novel somatic mouse model for hepatocellular carcinoma. Mol. Cell. Biol. 25: 1228.
24. Llovet J.M., Burroughs A., and Bruix J. 2003. Hepatocellular carcinoma. Lancet 362: 1907.
25. Lucito R., Healy J., Alexander J., Reiner A., Esposito D., Chi M., Rodgers L., Brady A., Sebat J., Troge J., West J.A., Rostan S., Nguyen K.C., Powers S., Ye K.Q., Olshen A., Venkatraman E., Norton L., and Wigler M. 2003. Representational oligonucleotide microarray analysis: A high-resolution method to detect genome copy number variation. Genome Res. 13: 2291.
26. Manickan E., Satoi J., Wang T.C., and Liang T.J. 2001. Conditional liver-specific expression of simian virus 40 T antigen leads to regulatable development of hepatic neoplasm in transgenic mice. J. Biol. Chem. 276: 13989.
27. Murakami H., Sanderson N.D., Nagy P., Marino P.A., Merlino G., and Thorgeirsson S.S. 1993. Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: Interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis. Cancer Res. 53: 1719.
28. Murakami Y., Hayashi K., Hirohashi S., and Sekiya T. 1991. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res. 51: 5520.
29. Nhieu J.T., Renard C.A., Wei Y., Cherqui D., Zafrani E.S., and Buendia M.A. 1999. Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am. J. Pathol. 155: 703.
30. Niketeghad F., Decker H.J., Caselmann W.H., Lund P., Geissler F., Dienes H.P., and Schirmacher P. 2001. Frequent genomic imbalances suggest commonly altered tumour genes in human hepatocarcinogenesis. Br. J. Cancer 85: 697.
31. Nishida N., Fukuda Y., Komeda T., Kita R., Sando T., Furukawa M., Amenomori M., Shibagaki I., Nakao K., and Ikenaga M., et al. 1994. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res. 54: 3107.
32. Nitou M., Sugiyama Y., Ishikawa K., and Shiojiri N. 2002. Purification of fetal mouse hepatoblasts by magnetic beads coated with monoclonal anti-e-cadherin antibodies and their in vitro culture. Exp. Cell Res. 279: 330.
33. Parkin D.M., Bray F., Ferlay J., and Pisani P. 2001. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 94: 153.
34. Pear W.S., Miller J.P., Xu L., Pui J.C., Soffer B., Quackenbush R.C., Pendergast A.M., Bronson R., Aster J.C., Scott M.L., and Baltimore D. 1998. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92: 3780.
35. Peng S.Y., Lai P.L., and Hsu H.C. 1993. Amplification of the c-myc gene in human hepatocellular carcinoma: Biologic significance. J. Formos. Med. Assoc. 92: 866.
36. Ponder K.P., Gupta S., Leland F., Darlington G., Finegold M., DeMayo J., Ledley F.D., Chowdhury J.R., and Woo S.L. 1991. Mouse hepatocytes migrate to liver parenchyma and function indefinitely after intrasplenic transplantation. Proc. Natl. Acad. Sci. 88: 1217.
37. Ray R.B., Steele R., Meyer K., and Ray R. 1997. Transcriptional repression of p53 promoter by hepatitis C virus core protein. J. Biol. Chem. 272: 10983.
38. Sage J., Miller A.L., Perez-Mancera P.A., Wysocki J.M., and Jacks T. 2003. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 424: 223.
39. Sandgren E.P., Quaife C.J., Pinkert C.A., Palmiter R.D., and Brinster R.L. 1989. Oncogene-induced liver neoplasia in transgenic mice. Oncogene 4: 715.
40. Schmitt C.A., Fridman J.S., Yang M., Baranov E., Hoffman R.M., and Lowe S.W. 2002a. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1: 289.
41. Schmitt C.A., Fridman J.S., Yang M., Lee S., Baranov E., Hoffman R.M., and Lowe S.W. 2002b. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109: 335.
42. Shachaf C.M., Kopelman A.M., Arvanitis C., Karlsson A., Beer S., Mandl S., Bachmann M.H., Borowsky A.D., Ruebner B., Cardiff R.D., Yang Q., Bishop J.M., Contag C.H., and Felsher D.W. 2004. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431: 1112.
43. Shafritz D.A. and Dabeva M.D. 2002. Liver stem cells and model systems for liver repopulation. J. Hepatol. 36: 552.
44. Silva J.M., Li M.Z., Chang K., Ge W., Golding M.C., Rickles R.J., Siolas D., Hu G., Paddison P.J., Schlabach M.R., Sheth N., Bradshaw J., Burchard J., Kulkarni A., Cavet G., Sachidanandam R., McCombie W.R., Cleary M.A., Elledge S.J., and Hannon G.J. 2005. Second-generation shRNA libraries covering the mouse and human genomes. Nat. Genet. 37: 1281.
45. Smalley M. and Ashworth A. 2003. Stem cells and breast cancer: A field in transit. Nat. Rev. Cancer 3: 832.
46. Steinberg P., Frank H., Odenthal M., Dienes H.P., and Seidel A. 1997. Role of the Ha-ras gene in the malignant transformation of rat liver oval cells. Int. J. Cancer 71: 680.
47. Tai M.H., Chang C.C., Kiupel M., Webster J.D., Olson L.K., and Trosko J.E. 2005. Oct4 expression in adult human stem cells: Evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 26: 495.
48. Thorgeirsson S.S. 1996. Hepatic stem cells in liver regeneration. FASEB J. 10: 1249.
49. Tsao M.S. and Grisham J.W. 1987. Hepatocarcinomas, cholangiocarcinomas, and hepatoblastomas produced by chemically transformed cultured rat liver epithelial cells. A light- and electron-microscopic analysis. Am. J. Pathol. 127: 168.
50. Ueda H., Ullrich S.J., Gangemi J.D., Kappel C.A., Ngo L., Feitelson M.A., and Jay G. 1995. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat. Genet. 9: 41.
51. Verna L., Whysner J., and Williams G.M. 1996a. 2-Acetyl-aminofluorene mechanistic data and risk assessment: DNA reactivity, enhanced cell proliferation and tumor initiation. Pharmacol. Ther. 71: 83.
52. _. 1996b. N-nitrosodiethylamine mechanistic data and risk assessment: Bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation. Pharmacol. Ther. 71: 57.
53. Wang R., Ferrell L.D., Faouzi S., Maher J.J., and Bishop J.M. 2001. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J. Cell Biol. 153: 1023.
54. Wang X.W., Forrester K., Yeh H., Feitelson M.A., Gu J.R., and Harris C.C. 1994. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl. Acad. Sci. 91: 2230.
55. Wong C.M., Fan S.T., and Ng I.O. 2001. β-Catenin mutation and overexpression in hepatocellular carcinoma: Clinicopathologic and prognostic significance. Cancer 92: 136.
56. Wong N., Lai P., Lee S.W., Fan S., Pang E., Liew C.T., Sheng Z., Lau J.W., and Johnson P.J. 1999. Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: Relationship to disease stage, tumor size, and cirrhosis. Am. J. Pathol. 154: 37.